Antibody ID	ANI0ZCCGZ
Antibody Name	Undisclosed
Antigen Name	.					Antigen Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Partial Response (PR)	15.90% (all) 33.30% (FOLR1/TRPV6 high)
Patients Enrolled	Patients with platinum-resistant ovarian cancer (OC), metastatic triple negative breast cancer (TNBC) and received median 3 prior regimens.
Administration Dosage	0.15, 0.17, 0.18 mg/kg day1 and day15; q28d.
Related Clinical Trial
NCT Number	NCT04740398	Clinical Status	Phase 1
Clinical Description	A phase 1a/1b, open-label, multi-center, first in human and expansion study to assess the safety, tolerance, and pharmacokinetics of the novel antitumor agent CBP-1008 in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Objective Response Rate (ORR)	44.20 50.00% (HER2-positive BC) 38.50% (HER2-Low BC) 66.70% (CRC) 50.00% (EsC) 50.00% (OC) 33.30% (EC)
Patients Enrolled	Pretreated advanced or metastatic solid tumors; Histologically confirmed HER2-positive or HER2- expressing cancers.
Administration Dosage	2.20 - 12.00 mg/kg Q3W.
Related Clinical Trial
NCT Number	NCT05150691	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2a, multicenter, open-label, non-randomized first in human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Objective Response Rate (ORR)	50.00% (all) 70.60% (breast cancer)
Patients Enrolled	Patients with advanced/metastatic HER2-positive solid tumors, who had progressed on, or were intolerant to prior standard therapies, with ECOG PS 2, and measurable disease,.
Administration Dosage	6 dose levels from 0.40 to 2.60 mg/kg Q3W.
Related Clinical Trial
NCT Number	NCT04257110	Clinical Status	Phase 1
Clinical Description	A first-in-human, open label, multiple dose, dose escalation and cohort expansion phase 1 study to investigate the safety, tolerability, pharmacokinetics and antitumor activities of bb-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[4]
Related Clinical Trial
NCT Number	NCT05642949	Clinical Status	Phase 1/2
Clinical Description	Phase 1/2, multi-center, open-label, dose escalation and cohort expansion study to evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB036C in participants with advanced or metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[5]
Related Clinical Trial
NCT Number	NCT05797168	Clinical Status	Phase 1/2
Clinical Description	FONTANA: A modular phase 1/2a, open-label, multi-center study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ascending doses of AZD5335 monotherapy and in combination with anti-cancer agents in participants with solid tumors.
Primary Endpoint	Number of participants with adverse events/serious adverse events, the number of participants with dose limiting toxicity (DLT).
Other Endpoint	Objective Response Rate (ORR), Duration of Response (DoR), Disease Control Rate (DCR), Progression free Survival (PFS), Overall Survival (OS).

Experiment 1 Reporting the Activity Date of This ADC					[6]
Related Clinical Trial
NCT Number	NCT04396340	Clinical Status	Phase 1/2
Clinical Description	A phase 1b, first-in-human, dose escalation and expansion study of XMT-1592 in patients with solid tumors likely to express NAPI2B.

Experiment 1 Reporting the Activity Date of This ADC					[7]
Related Clinical Trial
NCT Number	NCT05399654	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[8]
Related Clinical Trial
NCT Number	NCT04175847	Clinical Status	Phase 1/2
Clinical Description	To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.
Experiment 2 Reporting the Activity Date of This ADC					[9]
Patients Enrolled	Patients with malignant pleural mesothelioma and MSLN in advanced malignant solid tumors.
Administration Dosage	Dose of 0.10, 0.50, 1.00, 1.50, 2.00 and 2.50 mg/kg.
Related Clinical Trial
NCT Number	NCT04175847	Clinical Status	Phase 1/2
Clinical Description	To evaluate the safety of RC88 for injection in patients with advanced malignant solid tumors, multicenter, open, multi-cohort extension of efficacy and pharmacokinetic characteristics phase 1 /2a clinical study.
Experiment 3 Reporting the Activity Date of This ADC					[24]
Related Clinical Trial
NCT Number	NCT05508334	Clinical Status	Phase 1
Clinical Description	An open-label, non-randomised, multicentre study to allow continued access to and assess the safety and tolerability of RC88 for patients with advanced solid tumours.

Experiment 1 Reporting the Activity Date of This ADC					[10]
Related Clinical Trial
NCT Number	NCT05579366	Clinical Status	Phase 1/2
Clinical Description	Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[11]
Related Clinical Trial
NCT Number	NCT05721222	Clinical Status	Phase 1/2
Clinical Description	Phase 1/2 study of PRO1160 in patients with renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), or non-Hodgkin lymphoma (NHL).

Experiment 1 Reporting the Activity Date of This ADC					[12]
Related Clinical Trial
NCT Number	NCT05438329	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2a, multicenter, open-label, non-randomized first in human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1305 in subjects with advanced/metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[13]
Related Clinical Trial
NCT Number	NCT05320588	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2 study of BIO-106 as monotherapy or in combination with pembrolizumab in patients with advanced cancers (starbridge-1).

Experiment 1 Reporting the Activity Date of This ADC					[14]
Related Clinical Trial
NCT Number	NCT05217693	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[15]
Related Clinical Trial
NCT Number	NCT05276609	Clinical Status	Phase 1
Clinical Description	ARTEMIS-001: A phase 1, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and efficacy of multiple doses of intravenous administration of HS-20093 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy.

Experiment 1 Reporting the Activity Date of This ADC					[16]
Related Clinical Trial
NCT Number	NCT05263479	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HS-20089 in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[17]
Related Clinical Trial
NCT Number	NCT05525286	Clinical Status	Phase 1
Clinical Description	A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma.

Experiment 1 Reporting the Activity Date of This ADC					[18]
Related Clinical Trial
NCT Number	NCT05765032	Clinical Status	Phase 1
Clinical Description	An open label, multicenter, phase 1b/2 study of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors.
Experiment 2 Reporting the Activity Date of This ADC					[19]
Related Clinical Trial
NCT Number	NCT05594875	Clinical Status	Phase 1
Clinical Description	An open-label, multi-center phase 1 clinical study on the safety, tolerability, pharmacokinetics, and clinical activity of SHR-A1921 for injection in subjects with advanced solid tumors.
Experiment 3 Reporting the Activity Date of This ADC					[20]
Related Clinical Trial
NCT Number	NCT05154604	Clinical Status	Phase 1
Clinical Description	A phase 1 multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-a1921 in subjects with advanced malignant solid tumour.

Experiment 1 Reporting the Activity Date of This ADC					[21]
Related Clinical Trial
NCT Number	NCT05277168	Clinical Status	Phase 1
Clinical Description	An open-label, single-arm, multi-center phase 1/2a clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1904 in subjects with advanced solid tumors.
Experiment 2 Reporting the Activity Date of This ADC					[22]
Related Clinical Trial
NCT Number	NCT04928625	Clinical Status	Phase 1
Clinical Description	An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1904 in patients with advanced pancreatic cancer.
Experiment 3 Reporting the Activity Date of This ADC					[23]
Related Clinical Trial
NCT Number	NCT04877717	Clinical Status	Phase 1
Clinical Description	An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1904 in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[25]
Related Clinical Trial
NCT Number	NCT05205850	Clinical Status	Phase 1
Clinical Description	An open, multi-center phase 1/2a clinical study of RC118 for injection in patients with locally advanced unresectable or metastatic malignant solid tumors with positive expression of CLAUDIN 18.2.
Experiment 2 Reporting the Activity Date of This ADC					[26]
Related Clinical Trial
NCT Number	NCT04914117	Clinical Status	Phase 1
Clinical Description	Phase 1, first-in-human, multicentre, open-label study of RC118 for injection in patients with locally advanced unresectable/metastatic solid tumours.
Experiment 3 Reporting the Activity Date of This ADC					[27]
Related Clinical Trial
NCT Number	NCT03895112	Clinical Status	Phase 1
Clinical Description	Phase 1 study of AVID200 in patients with myelofibrosis (myeloproliferative neoplasms research consortium [MPN-RC] 118).

Experiment 1 Reporting the Activity Date of This ADC					[28]
Related Clinical Trial
NCT Number	NCT05564858	Clinical Status	Phase 1
Clinical Description	A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in subjects with advanced solid malignant tumors.

Experiment 1 Reporting the Activity Date of This ADC					[29]
Related Clinical Trial
NCT Number	NCT05747924	Clinical Status	Phase 1
Clinical Description	A randomized, double-blind, placebo-controlled, phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of AOC 1020 administered intravenously to adult participants with facioscapulohumeral muscular dystrophy (FSHD).

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 9.96% (Day 23)
Method Description	Ceralasertib=25 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	HCT 116 cells		CVCL_0291
Experiment 2 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42.76% (Day 35)
Method Description	Ceralasertib=25 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.70% (Day 23)
Method Description	CBX-12=5 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	Colon cancer cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.32% (Day 35)
Method Description	CBX-12=10 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 5 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.22% (Day 23)
Method Description	Ceralasertib=25 mg/kg + CBX-12=5 mg/kg.
In Vivo Model	Colon cancer CDX model
In Vitro Model	Colon cancer	Colon cancer cells		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.40% (Day 35)
Method Description	Ceralasertib=25 mg/kg + CBX-12=10 mg/kg.
In Vivo Model	Breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00%	High GPRC5D expression (GPRC5D+++)
Method Description	The inhibitory activity of LM-305 against cancer cell growth was evaluated in Multiple myeloma CDX model in vivo. The dose of LM-305 was 3 mg/kg.
In Vivo Model	Multiple myeloma CDX model
In Vitro Model	Multiple myeloma	Multiple myeloma cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-0.30 nM	High GPRC5D expression (GPRC5D+++)
Method Description	LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-0.30 nM	High GPRC5D expression (GPRC5D+++)
Method Description	LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
In Vitro Model	Plasma cell myeloma	MM1.R cells		CVCL_8794

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Objective Response Rate (ORR)	0.00%
Patients Enrolled	Patients with advanced metastatic or unresectable colorectal cancer.
Administration Dosage	SC-006-monotherapy, 2 to 12 ug/kg IV every 3 weeks.
Related Clinical Trial
NCT Number	NCT03035279	Clinical Status	Phase 1
Clinical Description	An open label phase 1 study of SC-006 as a single agent and in combination with ABBV-181 in subjects with advanced colorectal cancer.

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Objective Response Rate (ORR)	2.90%	High GPR20 expression (GPR20+++)
Patients Enrolled	Histopathologically documented unresectable and/or metastatic gastrointestinal stromal tumor (GIST) following treatment with standard of care, including imatinib.
Administration Dosage	1.6 mg/kg, 3.2 mg/kg, 4.8 mg/kg, 6.4 mg/kg, and 9.6 mg/kg intravenously on Day 1 of each 21-day cycle.
Related Clinical Trial
NCT Number	NCT04276415	Clinical Status	Phase 1
Clinical Description	Phase 1, multicenter, open-label, first-in-human study of DS-6157a in subjects with advanced gastrointestinal stromal tumor.
Primary Endpoint	MTD=6.40 mg/kg.
Other Endpoint	Median PFS=4.20 months (95% CI, 1.60-6.90), Objective response rate=2.86%, comprising 0 complete responses and 1 (2.86%) partial responses.

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Objective Response Rate (ORR)	11.40% (all)
Patients Enrolled	Patients with locally advanced or metastatic G, CRC, PDA, or BIL cancer, previously treated, ECOG PS 0-1, positive AG-7 expression was not required.
Administration Dosage	AbGn-107 administered iv Q4 weeks (from 0.10-1.20 mg/kg) and Q2 weeks (from 0.80-1.00 mg/kg).
Related Clinical Trial
NCT Number	NCT02908451	Clinical Status	Phase 1
Clinical Description	A phase 1 dose escalation study, with cohort expansion, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABGN-107 therapy in patients with chemo-refractory locally advanced, recurrent, or metastatic gastric, colorectal, pancreatic or biliary cancer.

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Objective Response Rate (ORR)	13.30% (all)
Patients Enrolled	Patients with advanced renal cell carcinoma or ovarian cancer. Patients had received a median of 4 prior systemic therapy.
Administration Dosage	First dose was 1.60 mg/kg followed by 3.20, 4.80, 6.40, 8.00, and 9.60 mg/kg every 3 weeks.
Related Clinical Trial
NCT Number	NCT04707248	Clinical Status	Phase 1
Clinical Description	Phase 1, two-part, multi-center, first-in-human study of DS-6000A in subjects with advanced renal cell carcinoma and ovarian tumors.

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Objective Response Rate (ORR)	13.3% (4.2 mg/kg)
Patients Enrolled	Patients with HER2-positive advanced breast cancer progressive to at least two kinds of prior anti-HER2 treatment.
Administration Dosage	0.30-4.80 mg/kg iv administered once every 3 weeks.
Related Clinical Trial
NCT Number	NCT03281824	Clinical Status	Phase 1
Clinical Description	Open-label, dose increase and phase 1 study of ALT-P7 to determine safety, tolerability, pharmacokinetics for HER2 positive metastatic breast cancer patients who have progressed on previous trastuzumab-based therapy.

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Objective Response Rate (ORR)	22.70% (all)
Patients Enrolled	Patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) were enrolled. Patients had received a median of 4 prior systemic therapy.
Administration Dosage	TRPH-222 was administered IV 0.60 to 5.60 mg/kg once every 3 weeks.
Related Clinical Trial
NCT Number	NCT03682796	Clinical Status	Phase 1
Clinical Description	Phase 1, multicenter, open-label study of the antibody-drug conjugate TRPH-222 in subjects with relapsed and/or refractory B-cell lymphoma.

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.00% (Day 28)	Positive CD22 expression (CD22+++/++)
Method Description	In WSU-DLCL2 xenografts once weekly intravenous (IV) dosing with 1 mg/kg TRPH-222.
In Vivo Model	Non-Hodgkin's lymphoma CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.00% (Day 28)	Positive CD22 expression (CD22+++/++)
Method Description	In Granta-519 xenografts,trph-222 was dosed at 10 mg/kg once weekly intravenous (IV).
In Vivo Model	Mantle cell lymphoma CDX model
In Vitro Model	Mantle cell lymphoma	Granta-519 cells		CVCL_1818
Experiment 3 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.00% (Day 28)	Positive CD22 expression (CD22+++/++)
Method Description	In SU-DHL-2 xenografts,trph-222 was dosed at 10 mg/kg once weekly intravenous (IV).
In Vivo Model	Diffuse large B cell lymphoma CDX model
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-2 cells		CVCL_9550
Experiment 4 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 28)	Positive CD22 expression (CD22+++/++)
Method Description	In SU-DHL-4 xenografts,trph-222 was dosed at 10 mg/kg once weekly intravenous (IV).
In Vivo Model	Diffuse large B cell lymphoma CDX model
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 5 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 28)	Positive CD22 expression (CD22+++/++)
Method Description	In WSU-DLCL2 xenografts once every three-week intravenous (IV) dosing with 10 mg/kg TRPH-222.
In Vivo Model	Non-Hodgkin's lymphoma CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 6 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 28)	Positive CD22 expression (CD22+++/++)
Method Description	In WSU-DLCL2 xenografts once weekly intravenous (IV) dosing with 10 mg/kg TRPH-222.
In Vivo Model	Non-Hodgkin's lymphoma CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 7 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 28)	Positive CD22 expression (CD22+++/++)
Method Description	In WSU-DLCL2 xenografts once weekly intravenous (IV) dosing with 3 mg/kg TRPH-222.
In Vivo Model	Non-Hodgkin's lymphoma CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Objective Response Rate (ORR)	42.20% (all) 52.90% (DLBCL) 26.30% (FL) 60.00% (MCL) 66.70% (MZL) 0.00% (SLL/CLL) 42.90% (0.50 mg/kg) 33.30% (1.00 mg/kg) 43.80% (1.50 mg/kg) 50.00% (1.80 mg/kg)
Patients Enrolled	CD20-positive B-cell non Hodgkin lymphoma (NHL) and had failed 2 prior lines of standard treatment.
Administration Dosage	Seven dose cohorts (0.10, 0.50, 1.00, 1.50, 1.80, 2.10, 2.30 mg/kg iv d1,q21d).
Related Clinical Trial
NCT Number	NCT05395533	Clinical Status	Phase 1
Clinical Description	A multicenter, single-arm, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and effectiveness of TRS005 in patients with relapsed or refractory CD20-positive B-NHL.

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Objective Response Rate (ORR)	75.00% (Gastric/GEJ Cancer)
Patients Enrolled	Patients with advanced malignant tumors.
Administration Dosage	Day 1 in 3-week (Q3W) cycle 3.40 mg/kg.
Related Clinical Trial
NCT Number	NCT04805307	Clinical Status	Phase 1
Clinical Description	An open-label, phase 1, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of CMG901 in subjects with advanced unresectable or metastatic solid tumor.

Experiment 1 Reporting the Activity Date of This ADC					[40]
Related Clinical Trial
NCT Number	NCT05785728	Clinical Status	Phase 1/2
Clinical Description	Phase 1/2, multicenter, open-label, first-in-human study of DB-1202 monotherapy in patients with advanced solid malignant tumors to evaluate the tolerability, safety, pharmacokinetics and antitumor activity.

Experiment 1 Reporting the Activity Date of This ADC					[41]
Related Clinical Trial
NCT Number	NCT04662580	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of ARX517, with randomized comparison to investigator's choice of treatment, in subjects with metastatic castration-resistant prostate cancer who are resistant or refractory to prior standard therapies.

Experiment 1 Reporting the Activity Date of This ADC					[42]
Related Clinical Trial
NCT Number	NCT05735496	Clinical Status	Phase 1
Clinical Description	A phase 1 study of TQB2102 injection in patients with advanced cancers.

Experiment 1 Reporting the Activity Date of This ADC					[43]
Patients Enrolled	Patients with metastatic non-small cell lung cancer (mNSCLC) with EGFRm (sensitizing L858R mutation or exon 19 deletions) or EGFR wild-type, or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Related Clinical Trial
NCT Number	NCT05647122	Clinical Status	Phase 1
Clinical Description	A phase 1, multicenter, open-label, first-in-human, dose escalation and expansion study of AZD9592 as monotherapy and in combination with anti-cancer agents in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[44]
Related Clinical Trial
NCT Number	NCT03062007	Clinical Status	Phase 1
Clinical Description	Open-label study of safety, tolerability and pharmacokinetics of multiple doses of BI-CON-02 in patients with HER2-positive metastatic breast cancer, previously treated with trastuzumab.

Experiment 1 Reporting the Activity Date of This ADC					[45]
Related Clinical Trial
NCT Number	NCT05156866	Clinical Status	Phase 1
Clinical Description	A phase 1, first in human, dose-escalation study of TORL-2-307-ADC in participants with advanced cancer.

Experiment 1 Reporting the Activity Date of This ADC					[46]
Related Clinical Trial
NCT Number	NCT05103683	Clinical Status	Phase 1
Clinical Description	A phase 1, first in human, dose-escalation study of TORL-1-23 in participants with advanced cancer.

Experiment 1 Reporting the Activity Date of This ADC					[47]
Related Clinical Trial
NCT Number	NCT05367635	Clinical Status	Phase 1
Clinical Description	A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SKB315 for injection in patients with advanced solid tumors expressing claudin 18.2.

Experiment 1 Reporting the Activity Date of This ADC					[48]
Related Clinical Trial
NCT Number	NCT05735275	Clinical Status	Phase 1
Clinical Description	Safety, tolerability, pharmacokinetics, and efficacy of SHR-A2102, in subjects with locally advanced or metastatic solid tumor malignancies: a phase 1 open-label, one-arm, multicenter study.
Experiment 2 Reporting the Activity Date of This ADC					[49]
Related Clinical Trial
NCT Number	NCT05701709	Clinical Status	Phase 1
Clinical Description	An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SHR-A2102 in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[50]
Related Clinical Trial
NCT Number	NCT05394818	Clinical Status	Phase 1
Clinical Description	An open-label, phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.
Experiment 2 Reporting the Activity Date of This ADC					[51]
Related Clinical Trial
NCT Number	NCT05114759	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label, multicenter clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[52]
Related Clinical Trial
NCT Number	NCT05113069	Clinical Status	Phase 1
Clinical Description	An open-label, single-arm, multicenter, phase 1 study to estimate the safety, tolerability, pharmacokinetics, and efficacy of SHR-A1912 in patients with b-cell lymphoma.

Experiment 1 Reporting the Activity Date of This ADC					[53]
Related Clinical Trial
NCT Number	NCT04665921	Clinical Status	Phase 1
Clinical Description	A phase 1 study of SGN-STNV in advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[54]
Related Clinical Trial
NCT Number	NCT05229900	Clinical Status	Phase 1
Clinical Description	A phase 1 study of SGN-ALPV in advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[55]
Related Clinical Trial
NCT Number	NCT05220748	Clinical Status	Phase 1
Clinical Description	A phase 1 first-in-human, drug-dose escalation study of RM-1995 photoimmunotherapy, as monotherapy or combined with pembrolizumab, in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.

Experiment 1 Reporting the Activity Date of This ADC					[56]
Related Clinical Trial
NCT Number	NCT03057418	Clinical Status	Phase 1
Clinical Description	Open-label study of safety, tolerability, pharmacokinetics and pharmacodynamics of auriim multiple doses in patients with recurrent/refractory -cell, CD20-positive non-hodgkin lymphoma of low tumor grade or with follicular lymphoma.

Experiment 1 Reporting the Activity Date of This ADC					[57]
Related Clinical Trial
NCT Number	NCT05720117	Clinical Status	Phase 1
Clinical Description	A first-in-human, open-label, multicenter, phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PYX-201 in participants with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[58]
Related Clinical Trial
NCT Number	NCT03159117	Clinical Status	Phase 1
Clinical Description	A phase 1 open-label dose escalation of GD3 ADC (PFIZER PF-06688992) in subjects with unresectable stage 3 or stage 4 malignant melanoma (b802wi209568).

Experiment 1 Reporting the Activity Date of This ADC					[59]
Related Clinical Trial
NCT Number	NCT05652868	Clinical Status	Phase 1
Clinical Description	A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.

Experiment 1 Reporting the Activity Date of This ADC					[60]
Related Clinical Trial
NCT Number	NCT05174637	Clinical Status	Phase 1
Clinical Description	A phase study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[61]
Related Clinical Trial
NCT Number	NCT05394675	Clinical Status	Phase 1
Clinical Description	A phase 1, first-in-human study of DS-9606a in patients with tumor types known to express claudin-6 (CLDN6).

Experiment 1 Reporting the Activity Date of This ADC					[62]
Patients Enrolled	Metastatic breast cancer.
Administration Dosage	1.00 mg/kg.
Related Clinical Trial
NCT Number	NCT05261269	Clinical Status	Phase 1
Clinical Description	A dose-escalation study of the safety and pharmacology of dan-222 in subjects with metastatic breast cancer.

Experiment 1 Reporting the Activity Date of This ADC					[63]
Patients Enrolled	Patients with previously treated progressive locally advanced or metastatic solid tumors, MET positive.
Related Clinical Trial
NCT Number	NCT05323045	Clinical Status	Phase 1
Clinical Description	A first-in-human dose-escalation and expansion trial with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-met expressing locally advanced or metastatic solid tumours.

Experiment 1 Reporting the Activity Date of This ADC					[64]
Related Clinical Trial
NCT Number	NCT05631964	Clinical Status	Phase 1
Clinical Description	A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and initial efficacy of BL-M07D1 for injection in patients with locally advanced or metastatic digestive tract tumors and other solid tumors.
Experiment 2 Reporting the Activity Date of This ADC					[65]
Patients Enrolled	Patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors.
Related Clinical Trial
NCT Number	NCT05461768	Clinical Status	Phase 1
Clinical Description	A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M07D1 injection in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[66]
Related Clinical Trial
NCT Number	NCT05385692	Clinical Status	Phase 1
Clinical Description	Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic gastrointestinal tumors or other solid tumors.
Experiment 2 Reporting the Activity Date of This ADC					[67]
Related Clinical Trial
NCT Number	NCT05339685	Clinical Status	Phase 1
Clinical Description	Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of injectable BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[68]
Related Clinical Trial
NCT Number	NCT05405621	Clinical Status	Phase 1
Clinical Description	A phase 1, multi-center, open-label study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of BAT8009 in patients with advanced solid tumours.

Experiment 1 Reporting the Activity Date of This ADC					[69]
Related Clinical Trial
NCT Number	NCT05378737	Clinical Status	Phase 1
Clinical Description	A multicenter, open phase 1 clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BAT8006 for injection in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[70]
Related Clinical Trial
NCT Number	NCT05718895	Clinical Status	Phase 1
Clinical Description	An open, multi-center, phase 1 clinical study of ATG 022 in patients with advanced/metastatic solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[71]
Related Clinical Trial
NCT Number	NCT05498597	Clinical Status	Phase 1
Clinical Description	First-in-human, phase 1 study of AMT-151, an anti-folate receptor alpha antibody-drug conjugate, in patients with selected advanced solid tumours.

Experiment 1 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.60% (Day 28)	High TM4SF1 expression (TM4SF1+++)
Method Description	Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model	Pancreatic cancer CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	MIA PaCa-2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.40% (Day 23)	High TM4SF1 expression (TM4SF1+++)
Method Description	Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model	Pancreatic cancer CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	MIA PaCa-2 cells		CVCL_0428
Experiment 3 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.50% (Day 23)	High TM4SF1 expression (TM4SF1+++)
Method Description	Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model	Breast ductal cancer CDX model
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.60% (Day 33)	High TM4SF1 expression (TM4SF1+++)
Method Description	Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model	Breast ductal cancer CDX model
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 5 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.10% (Day 23)	High TM4SF1 expression (TM4SF1+++)
Method Description	Mice bearingeither CALU-3 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model	Lung adenocarcinoma CDX model
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609

Experiment 1 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 nM	High TM4SF1 expression (TM4SF1+++)
Method Description	The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ cell lines.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 2 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 nM	High TM4SF1 expression (TM4SF1+++)
Method Description	The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ solid tumor cell lines.
In Vitro Model	Pancreatic ductal adenocarcinoma	MIA PaCa-2 cells		CVCL_0428

Experiment 1 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 15)	Positive CD33 expression (CD33+++/++)
Method Description	EOL-1 tumor-bearing mice received a single intravenous bolus administration of vehicle, IMGN779, or Ab-DGN462, with each conjugate molecule dosed at approximately 1.5 mg/kg ADC by antibody concentration (i.e., 10 or 30 ug/kg linked IGN).
In Vivo Model	EOL-1 CDX model
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258
Experiment 2 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 30)	Positive CD33 expression (CD33+++/++)
Method Description	IMGN779 (0.5 mg/kg, a single dose) induces efficient tumor cell killing in cell line-derived models of MV4-11 cells with CD33 expression with high expression.
In Vivo Model	MV4-11 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 13.33% (Day 30	Positive CD46 expression (CD46 +++/++)
Method Description	In vivo efficacy of PNU-conjugated ADCs in NSCLC LU253 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg HuIgG1-19 ADC.
In Vivo Model	Non-small cell lung cancer PDX model (PDX: LU253 PDX)
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 21.34% (Day 15)	Positive CD46 expression (CD46 +++/++)
Method Description	In vivo efficacy of PNU-conjugated ADCs in colorectal CR188 PDX subcutaneous models in NOD/SCID mice. A single dose of 1.0 mg/kg HuIgG1-19 ADC.
In Vivo Model	Colorectal cancer PDX model (PDX: CR188 PDX)

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3.00 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.80 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.63%±9.71%	Positive EGFR expression (EGFR+++/++)
Method Description	PDX mice were administrated vehicle or DTLL at the LDMequivalent dose of 0.1 mg/kg once a week for 3 wk. Tumor volumes were measured after animals were sacrificed on Days 24 and 39, respectively. DTLL was administered via tail vein injection once a week for three weeks.
In Vivo Model	Pancreatic cancer PDX model (PDX: PA1338)

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 14.30% (Day 21)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 19.40% (Day 14)	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Tumor Growth Inhibition value (TGI)	30.00% (Day 20)	High FOLR1 expression (FOLR1+++; 4,500,000 FOLR1 molecules/cell)
Method Description	Animals with established tumors of about 130 mm3 were treated with intravenous single injection of the M9346A-DM conjugates at 50 mg/kg, equivalent to 82 g conjugated maytansinoid per kg The conjugates were injected on day 4 after cell inoculation.
In Vivo Model	FRalpha-positive KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 32.80% (Day 13)	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 37.80% (Day 13)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 44.00% (Day 13)	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 55.20% (Day 21)	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 78.40% (Day 21)	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.55% (Day 25)
Method Description	C57BL/6-albino mice were subcutaneously inoculated with 5x105 MC38 on the right flank. Once the tumors had reached an average volume of approximately 125 mm3 as determined by measuring with a caliper, the mice were randomly divided into groups after which 100 g AU-011 in 100 uL was administered intravenously into the tail vein or intraperitoneally, or 30 g AU-011 in 30 L was administered intratumorally.    Click to Show/Hide
In Vivo Model	MC38 CDX model
In Vitro Model	Mouse colon adenocarcinoma	MC-38 cells		CVCL_B288

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 57.10% (Day 21)	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 85.70% (Day 21)	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.11% (Day 12)
Method Description	The inhibitory activity of 1B-3R conjugate against cancer cell growth was evaluated in various human cancer cell lines in vivo.
In Vivo Model	Colorectal cancer CDX model
In Vitro Model	Colorectal cancer	Colorectal cancer cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 57.90% (Day 21)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 95.00% (Day 13)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67.80% (Day 40)	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 40)	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 40)	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 70.60% (Day 14)	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 74.20% (Day 14)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 93.50% (Day 14)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.50% (Day 30)	Positive PSMA expression (PSMA +++/++)
Method Description	In order to specify the pharmacological properties of MMAE.VC.SA.617 we inoculated LNCaP cells into NOD/SCID mice to generate a xenograft model. In vivo therapeutic efficacy studies were conducted with MMAE.VC.SA.617, namely 1.0 mg/kg (corresponding to 0.49 mg MMAE).
In Vivo Model	LNCaP CDX model
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395

Experiment 1 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.10% (Day 40)	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 40)	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 40)	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.57% (Day 30)	High LGALS3BP expression (LGALS3BP +++)
Method Description	Gch6 cell xenograft mice were intravenously treated with 10 mg/kg 1959-sss/DM4 twice weekly for a total of three injections.
In Vivo Model	Gch6 CDX model
In Vitro Model	Glioblastoma	Gch6 cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.02 nM	High LGALS3BP expression (LGALS3BP +++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human glioblastoma cell lines.
In Vitro Model	Glioblastoma	Gch14 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.57 nM	High LGALS3BP expression (LGALS3BP +++)
Method Description	In vitro cytotoxicity of ADCs against a panel of four multiple human glioblastoma cell lines.
In Vitro Model	Glioblastoma	Gch6 cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 100.00% (Day 14)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 100.00% (Day 14)	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0.00%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0.00% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0.00% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0.00% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0.00% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 56.70% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 15.20% (Day 13)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 16.70% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 16.70% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 94.70% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 21.70% (Day 13)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 64.60% (Day 13)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 70.20% (Day 13)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 87.30% (Day 14)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 87.40% (Day 13)	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.80 pM	Positive CCR4 expression (CCR4 +++/++)
Method Description	In vitro efficacy comparison of the CCR4 IT vs IL2 fusion toxin to human CCR4+ CTCL Hut102/6TG using luminescent cell viability assay.
In Vitro Model	Cutaneous T cell lymphoma	HUT102/6TG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.40 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30.40 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	48.20 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.10 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	57.80 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	112.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.30 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	51.60 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	107.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	31.60 pM	Positive CCR4 expression (CCR4 +++/++)
Method Description	In vitro efficacy comparison of the CCR4 IT vs IL2 fusion toxin to human CCR4+ CTCL Hut102/6TG using luminescent cell viability assay.
In Vitro Model	Cutaneous T cell lymphoma	HUT102/6TG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	34.40 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.30 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	178.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37.50 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	60.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	211.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	41.40 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	598.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.01 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	45.50 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.20 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	165.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	46.50 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	67.10 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	371.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	47.90 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	92.50 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	426.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	50.80 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79.80 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	247.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.20 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.50 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	98.30 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.80 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	61.70 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	117.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.70 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	55.10 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	77.40 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	66.70 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	72.70 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.38 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	67.40 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	75.10 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	74.30 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	219.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	294.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79.70 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	189.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	114.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	156.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	158.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	131.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	137.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	153.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	156.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	170.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	184.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	218.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	225.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.29 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	356.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	405.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	370.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	509.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	485.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	740.00 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	47.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.52 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.21 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	61.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.29 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12.00 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.00 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23.00 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	34.00 nM	High EGFR expression (EGFR+++)
Method Description	The effect of MMAE-conjugated cetuximab ADCs on the viability of U87 glioblastoma cells that express EGFR.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[90]
Efficacy Data	Half Maximal Effective Concentration (EC50)	25.00 pM	Positive CLL-1 expression (CLL-1+++/++)
Method Description	In vitro cytotoxicity of the anti-hCLL-1 ARC-ADCs was then evaluated using human AML cell lines U937 (CLL-1+) and KG1a (CLL-1-1).
In Vitro Model	Adult acute monocytic leukemia	U-937 cells		CVCL_0007

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1000 pM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.10 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 pM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 3.00 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.40 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Uterine sarcoma	MES-SA cells		CVCL_1404
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.00 nM	Positive CD46 expression (CD46 +++/++)
Method Description	Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[91]
Efficacy Data	Objective Response Rate (ORR)	20.00%	Positive CD70 expression (CD70+++/++)
Patients Enrolled	CD70-positive MCL or DLBCL including FL3b (expression in at least 50% of the sample)
Administration Dosage	8 mg/kg (up to a maximum of 200 mg) intravenously once every 3 weeks.
Related Clinical Trial
NCT Number	NCT02216890	Clinical Status	Phase 1
Clinical Description	Safety study of SGN-CD70A in cancer patients.
Primary Endpoint	Objective response rate=20.00% (95% CI 5.70-43.70).
Other Endpoint	Median progression free survival=1.90 months.

Experiment 1 Reporting the Activity Date of This ADC					[92]
Related Clinical Trial
NCT Number	NCT02575781	Clinical Status	Phase 1
Clinical Description	A first-in-human phase 1 dose escalation study of SAR428926 in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[93]
Patients Enrolled	Patients with advanced cancer (Colorectal Cancer or Gastric Cancer).
Administration Dosage	SC-007 iv.
Related Clinical Trial
NCT Number	NCT03253185	Clinical Status	Phase 1
Clinical Description	An open label study of SC-007 in subjects with advanced cancer.

Experiment 1 Reporting the Activity Date of This ADC					[94]
Related Clinical Trial
NCT Number	NCT03076372	Clinical Status	Phase 1
Clinical Description	A phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[95]
Related Clinical Trial
NCT Number	NCT01065623	Clinical Status	Phase 1
Clinical Description	An open label phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY79-4620 administered as an intravenous infusion once every 2 weeks in patients with advanced solid tumors.
Experiment 2 Reporting the Activity Date of This ADC					[96]
Related Clinical Trial
NCT Number	NCT01028755	Clinical Status	Phase 1
Clinical Description	An open label phase 1 study to evaluate the safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY79-4620 in patients with advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[97]
Related Clinical Trial
NCT Number	NCT03884517	Clinical Status	Phase 1
Clinical Description	An open, escalating phase 1 clinical trial of BAT8003 (for injection) on the safety, tolerability and pharmacokinetics for patients with advanced epithelial cancer.